Laziros (Azacitidine)

Azacitidine blocks DNA methyltransferase enzymes, leading to reduced methylation of DNA. This demethylation reactivates tumor‑suppressor genes that had been silenced. Additionally, the drug is incorporated into RNA and DNA during cell division, causing direct cytotoxic effects on rapidly proliferating malignant cells.

The specific dose and schedule of Laziros are determined by the treating physician based on the patient’s diagnosis, disease severity, renal and hepatic function, and overall health status. Dosing is individualized and should follow the prescriber’s written instructions.

Azacitidine is classified as contraindicated in pregnancy because it may cause fetal harm. Women of childbearing potential should use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while receiving treatment.

To request Laziros, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Laziros belongs to the class of DNA methyltransferase inhibitors, a distinct mechanism from conventional chemotherapy or targeted agents. Compared with intensive chemotherapy, azacitidine offers a less aggressive approach with oral‑like tolerability, making it suitable for older or frail patients, though response rates vary by disease subtype.

Laziros must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before administration, the product is reconstituted according to the manufacturer’s instructions and used promptly.

Laziros is supplied as a sterile powder for injection that is reconstituted with a suitable diluent. The prepared solution is given by subcutaneous injection, typically in the abdomen or thigh, according to the dosing schedule prescribed by the treating physician.

The most serious adverse events include tumor lysis syndrome, severe infections due to immunosuppression, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, rapid metabolic changes, or allergic responses during therapy.

Laziros is contraindicated in patients with known hypersensitivity to azacitidine or any component of the formulation. It should also be avoided in individuals with uncontrolled active infections, pregnant women, and patients receiving live attenuated vaccines without appropriate medical supervision.